Complete remission of philadelphia chromosome-positive acute myeloid leukemia with imatinib mesylate.
- Author:
Saet Byul JANG
1
;
Sung Hwa BAE
;
Hye Ryun JUNG
;
So Yeon YOON
;
Eon Ju JUN
;
Gun Woo KANG
;
Hun Mo RYOO
Author Information
1. Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea. rhmrhm@cu.ac.kr
- Publication Type:Case Report
- Keywords:
Leukemia;
Myeloid;
Acute;
Philadelphia chromosome;
Imatinib mesylate
- MeSH:
Benzamides;
Cytogenetics;
Humans;
Leukemia;
Leukemia, Myeloid, Acute;
Mesylates;
Philadelphia;
Philadelphia Chromosome;
Piperazines;
Prognosis;
Pyrimidines;
Rare Diseases;
RNA, Messenger;
Imatinib Mesylate
- From:Korean Journal of Medicine
2010;78(1):132-137
- CountryRepublic of Korea
- Language:English
-
Abstract:
Philadelphia chromosome-positive acute myeloid leukemia (Ph+AML) is a rare disease characterized by a poor prognosis with resistance to standard chemotherapy. We report a patient with Ph+AML with a minor BCR-ABL-positive mRNA transcript who achieved a hematologic, cytogenetic, and major molecular complete response after cytarabine-based chemotherapy followed by imatinib. After more than 6 months of continuous imatinib therapy, the patient is in continuous complete remission. Our results show that imatinib mesylate is effective in treating Ph+AML.
